Bringing innovative ADC and SMDC medicines to cancer patients around the world
Founded in 2018, CanWell Pharma is led by several highly accomplished veterans who have an average of 25 years of experience in drug discovery and development in both U.S. and China biopharmaceutical industries. CanWell is dedicated to developing its proprietary first-in-class and best-in-class oncology products to address difficult-to-treat advanced cancers. CanWell is developing a rich R&D pipelines under our technology platforms.
Our Mission
Our mission at CanWell is to develop innovative treatments that harness the power of the immune system to fight cancer. We are devoted to leveraging the latest advances to further explore and develop a variety of innovative therapies. With a focus on collaboration, innovation and patient-centered care, we strive to be at the forefront of cancer therapy and bring new hope to patients and their families.
Antibody Drug Conjugate
Small Molecule Drug Conjugate
Latest News
A novel Dual-payload HER2 Targeted ADC, CAN016 as a Clinical Candidate to Overcome Enhertu Resistance
Resistance to ADC Enhertu (DS-8201) therapy presents a significant clinical challenge for patients with HER2-positive cancers. To address this unmet need, we have developed a novel dual-payload ADC (CAN016), conjugating both MMAE and exatecan to a HER2 antibody, based on our proprietary StarLinkerTM…
CanWell Pharma Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, CA – CanWell Pharma is pleased to announce its participation in the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), taking place from January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco. As one of the world’s most prestigious healthcare investment symposium…
Preliminary Results of CanWell’s CAN1012 (an IFNα-biased TLR7 Agonist) in Combination with Toripalimab was Presented at ESMO 2025
The 2025 European Society for Medical Oncology (ESMO) Annual Congress was held in Oct 17-19, Berlin, Germany. CanWell presented preliminary safety and efficacy data from its Phase 1b/2a clinical trial of CAN1012, a first-in-class IFNα-biased TLR7 agonist, in combination with toripalimab for advanced…
CanWell will Present Latest ADC Program Updates at 16th World ADC in San Diego, CA (Nov 3-6, 2025)
CanWell Pharma will present its latest development progress at the 16th World ADC held on Nov 3-6, 2025, in San Diego, CA. The presentation will be in the form of a poster. The poster will cover the newest research and development updates on company StarLinker dual/tri-payload ADCs, which had made s…